56 related articles for article (PubMed ID: 27720938)
21. A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.
Suleiman AA; Frechen S; Scheffler M; Zander T; Nogova L; Kocher M; Jaehde U; Wolf J; Fuhr U
AAPS J; 2015 Nov; 17(6):1483-91. PubMed ID: 26286677
[TBL] [Abstract][Full Text] [Related]
22. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
[TBL] [Abstract][Full Text] [Related]
23. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.
Dancer J; Takei H; Ro JY; Lowery-Nordberg M
Oncol Rep; 2007 Jul; 18(1):151-5. PubMed ID: 17549361
[TBL] [Abstract][Full Text] [Related]
24. Substance P receptor blocker, aprepitant, inhibited cutaneous and other neurogenic inflammation side effects of the EGFR1-TKI, erlotinib.
Chmielinska JJ; Kramer JH; Mak IT; Spurney CF; Weglicki WB
Mol Cell Biochem; 2020 Feb; 465(1-2):175-185. PubMed ID: 31853800
[TBL] [Abstract][Full Text] [Related]
25. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
[TBL] [Abstract][Full Text] [Related]
26. A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.
Kumar R; Lu SK; Minchom A; Sharp A; Davidson M; Gunapala R; Yap TA; Bhosle J; Popat S; O'Brien ME
Cancer Chemother Pharmacol; 2016 Feb; 77(2):375-83. PubMed ID: 26706729
[TBL] [Abstract][Full Text] [Related]
27. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
[TBL] [Abstract][Full Text] [Related]
28. Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer.
Grüner BM; Winkelmann I; Feuchtinger A; Sun N; Balluff B; Teichmann N; Herner A; Kalideris E; Steiger K; Braren R; Aichler M; Esposito I; Schmid RM; Walch A; Siveke JT
Mol Cancer Ther; 2016 May; 15(5):1145-52. PubMed ID: 26823494
[TBL] [Abstract][Full Text] [Related]
29. Microarray analysis of gene expression profile of multidrug resistance in pancreatic cancer.
Zhao YP; Chen G; Feng B; Zhang TP; Ma EL; Wu YD
Chin Med J (Engl); 2007 Oct; 120(20):1743-52. PubMed ID: 18028764
[TBL] [Abstract][Full Text] [Related]
30. Erlotinib Promotes Ligand-Induced EGFR Degradation in 3D but Not 2D Cultures of Pancreatic Ductal Adenocarcinoma Cells.
Betriu N; Andreeva A; Semino CE
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572731
[TBL] [Abstract][Full Text] [Related]
31. Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin.
Akoglu G; Yavuz SO; Metin A
Indian J Pharmacol; 2016; 48(3):324-6. PubMed ID: 27298507
[TBL] [Abstract][Full Text] [Related]
32. Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase.
Sharma N; Bhushan A; He J; Kaushal G; Bhardwaj V
Cancer Metab; 2020; 8():19. PubMed ID: 32974013
[TBL] [Abstract][Full Text] [Related]
33. Cutaneous Toxicity Induced by Hibiscus Tea in a Patient Treated with Erlotinib.
Jacquin-Porretaz C; Gérard B; Nardin C; Drobacheff-Thiebaut C; Blanc D; Jacoulet P; Westeel V; Aubin F
J Thorac Oncol; 2017 May; 12(5):e47-e48. PubMed ID: 28434514
[No Abstract] [Full Text] [Related]
34. Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics.
Martín-Blázquez A; Jiménez-Luna C; Díaz C; Martínez-Galán J; Prados J; Vicente F; Melguizo C; Genilloud O; Pérez Del Palacio J; Caba O
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32325731
[TBL] [Abstract][Full Text] [Related]
35. Identification of Clonal Neoantigens Derived From Driver Mutations in an
Wu D; Liu Y; Li X; Liu Y; Yang Q; Liu Y; Wu J; Tian C; Zeng Y; Zhao Z; Xiao Y; Gu F; Zhang K; Hu Y; Liu L
Front Immunol; 2020; 11():1366. PubMed ID: 32793190
[TBL] [Abstract][Full Text] [Related]
36. TRIM56 promotes malignant progression of glioblastoma by stabilizing cIAP1 protein.
Yang X; Zhang Y; Xue Z; Hu Y; Zhou W; Xue Z; Liu X; Liu G; Li W; Liu X; Li X; Han M; Wang J
J Exp Clin Cancer Res; 2022 Dec; 41(1):336. PubMed ID: 36471347
[TBL] [Abstract][Full Text] [Related]
37. Effects of paternal methionine supplementation on sperm DNA methylation and embryo transcriptome in sheep.
Townsend J; Braz CU; Taylor T; Khatib H
Environ Epigenet; 2023; 9(1):dvac029. PubMed ID: 36727109
[TBL] [Abstract][Full Text] [Related]
38. The role of SELENBP1 and its epigenetic regulation in carcinogenic progression.
Zhang Y; He Q
Front Genet; 2022; 13():1027726. PubMed ID: 36386843
[TBL] [Abstract][Full Text] [Related]
39. Impact of posttranslational modifications in pancreatic carcinogenesis and treatments.
Chen N; Zheng Q; Wan G; Guo F; Zeng X; Shi P
Cancer Metastasis Rev; 2021 Sep; 40(3):739-759. PubMed ID: 34342796
[TBL] [Abstract][Full Text] [Related]
40. Structural Perspectives of the CYP3A Family and Their Small Molecule Modulators in Drug Metabolism.
Wright WC; Chenge J; Chen T
Liver Res; 2019 Dec; 3(3-4):132-142. PubMed ID: 32789028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
